Jeanne V Moody

This inventor holds 5 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Arena Pharmaceuticals, Inc., H. Lundbeck A/s. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeanne V Moody. Retrieved from https://idiyas.com/inventor/jeanne-v-moody

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 9.2

ph-index = 3

Forward Citations = 43(Granted Patents)

Company Filing History:

3 out of 218

Arena Pharmaceuticals, Inc.

Years Active: 2013-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378219 - Crystalline forms of a MAGL inhibitor (2025-08-05),

2. 11434222 - MAGL inhibitors (2022-09-06),

3. 9522133 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2016-12-20),

4. 9126932 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2015-09-08),

5. 8580841 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2013-11-12),

Title: Inventor Jeanne V Moody: Pioneering Advances in Pharmaceutical Innovations

Introduction

Jeanne V Moody, a notable inventor based in San Diego, California, has made significant contributions to the field of pharmaceuticals, with a total of four patents to her name. Her innovative work focuses on developing compounds that can address various diseases and disorders through advanced therapeutic mechanisms.

Latest Patents

Among her latest inventions, Jeanne has developed MAGL inhibitors that introduce substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds. These innovative compounds have proven to be beneficial in treating diseases that can be ameliorated by the inhibition of MAGL. Additionally, her patent on substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl acetic acid derivatives shows potential in treating autoimmune and inflammatory disorders. This invention includes formulations that act as agonists of the S1P1 receptor, targeting conditions like psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, among others.

Career Highlights

Throughout her career, Jeanne has collaborated with leading pharmaceutical companies, including Arena Pharmaceuticals, Inc. and H. Lundbeck A/S. Her work has not only contributed to her personal accolades but has also advanced the capabilities and treatment options available within the pharmaceutical industry.

Collaborations

Jeanne has worked alongside esteemed colleagues, including Daniel J Buzard and Robert M Jones. These collaborations have facilitated her research and development efforts, further enriching her innovative approaches to tackling complex medical challenges.

Conclusion

Jeanne V Moody is a prominent figure in the realm of pharmaceutical innovations. Her patents not only showcase her inventive spirit but also highlight her commitment to developing effective treatments for various serious health conditions. As she continues to contribute to the field, her work will undoubtedly inspire future generations of inventors and researchers striving to push the boundaries of science and medicine.

Profile summary based on public USPTO records.